Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What's the scoop with Ate

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Dec 10, 2020 4:19pm

105 Views

Post# 32079305

RE:What's the scoop with Ate

These are all strategic moves that are prepping the stage for some news. So, selling now may be a poor idea. They've increased the size of the audience, so that when something drops (that's positive), the demand will be greater, therefore driving up the price.

Selling now based on these strategic moves that were never really meant to drive up the price may be premature.

I've been trying to pick up more shares here and there. But, that too could be foolish.

Time will tell.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario